Serum aminotransferase activity in patients of epilepsy and mania taking sodium valproate.
Keywords:
Aminotransferase, Epilepsy, Mania, Sodium Valproate
Abstract
Background: Our aim is to study the serum aminotransferase activity in patients of epilepsy and mania taking sodium valproate. Sodium valproate is a common drug to be prescribed to the patients of epilepsy and mania. Aminotransferase, both AST (Aspartate amino transferase) and ALT (Alanine amino transferase) is an accepted marker for any liver injury.Methods: Serum sample of fifty patients of known cases of epilepsy and mania, who were on sodium valproate since at least 3 month and fifty normal subjects were taken. Serum aminotransferase level (both AST & ALT) were estimated by colorimetric method in fully automated Erba XL-640 Analyser.Results: The level of aminotransferase enzymes were increased in patients of epilepsy and mania after administration of sodium valproate and elevation was highly significant as compared to the normal subjects (p value <0.05).Conclusion: From our study it is concluded that there is a need for monitoring serum aminotransferase level in patients receiving sodium valproate.References
1. Nikalje A, Ghodke M, Girbane A. GABA modulating agents: a brief review. Asian Journal of Biological Sciences 2011; 4: 201-20.
2. Ahmad M. Epilepsy: stigma and management. Current Research in Neuroscience 2011;201:1-14.
3. Arroyo S, de la Morena A. Life-threatening adverse events of antiepileptic drugs. Epilepsy Research 2001;47:155-74
4. Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure 2006; 15: 156-64.
5. Lee WM. Drug-induced hepatotoxicity. New England Journal of Medicine 2003; 349:474-85.
6. Bergmeyer HU, Horder M, Rej R. Clin. Chem. Clin. Biochem. 1986;24:481-95.
7. Henry RJ, Cannon DC, Winkerman JW. Clinical Chemistry Principle and Tech-niques, 2nd. Edn. Hagerstown MD., harper and Raw. 1974
8. Teitz NW. Clinical Guide to Laboratory tests. 3rd ed, W.B. Saunders. Philadelphia USA, 1995.
9. Verma NP, Haidukewych D. Differential but infrequent alterations of hepatic en-zyme levels and thyroid hormone levels by anticonvulsant drugs. Archives of Neurology 1994;51:381-4.
10. Spiller HA, Spiller H, Krenzelok EP, Klein-Schwartz W, Winter ML, Weber JA, et al. Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. Clinical Toxicology 2000; 38: 755-60.
11. Sussman NM. Hepatotoxicity of valproic acid. Neurology 1979;29:601.
12. Felker BL, Sloan KL, Dominitz JA, Barnes RF. The safety of valproic acid use for patients with hepatitis c infection. American Journal of Psychatry 2003;160:174-8.
13. Willmore LJ, Wilder BJ, Bruni J, Villarreal HJ. Effect of valproic acid on hepatic function. Neurology 1978;28: 961-4.
14. Boelsterli UA, Lim PLK. Mitochondrial abnormalities: a link to idiosyncratic drug hepatotoxicity. Toxicology. 2007; 220: 92 -107.
2. Ahmad M. Epilepsy: stigma and management. Current Research in Neuroscience 2011;201:1-14.
3. Arroyo S, de la Morena A. Life-threatening adverse events of antiepileptic drugs. Epilepsy Research 2001;47:155-74
4. Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure 2006; 15: 156-64.
5. Lee WM. Drug-induced hepatotoxicity. New England Journal of Medicine 2003; 349:474-85.
6. Bergmeyer HU, Horder M, Rej R. Clin. Chem. Clin. Biochem. 1986;24:481-95.
7. Henry RJ, Cannon DC, Winkerman JW. Clinical Chemistry Principle and Tech-niques, 2nd. Edn. Hagerstown MD., harper and Raw. 1974
8. Teitz NW. Clinical Guide to Laboratory tests. 3rd ed, W.B. Saunders. Philadelphia USA, 1995.
9. Verma NP, Haidukewych D. Differential but infrequent alterations of hepatic en-zyme levels and thyroid hormone levels by anticonvulsant drugs. Archives of Neurology 1994;51:381-4.
10. Spiller HA, Spiller H, Krenzelok EP, Klein-Schwartz W, Winter ML, Weber JA, et al. Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. Clinical Toxicology 2000; 38: 755-60.
11. Sussman NM. Hepatotoxicity of valproic acid. Neurology 1979;29:601.
12. Felker BL, Sloan KL, Dominitz JA, Barnes RF. The safety of valproic acid use for patients with hepatitis c infection. American Journal of Psychatry 2003;160:174-8.
13. Willmore LJ, Wilder BJ, Bruni J, Villarreal HJ. Effect of valproic acid on hepatic function. Neurology 1978;28: 961-4.
14. Boelsterli UA, Lim PLK. Mitochondrial abnormalities: a link to idiosyncratic drug hepatotoxicity. Toxicology. 2007; 220: 92 -107.
Published
2014-07-17
Issue
Section
Original Article
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
